Skip to main content
    E

    Enovis Corp (ENOV)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $27.93
    +0.25 (+0.90%)

    Market Cap: $1.60B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enovis Corp (ENOV) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Enovis (ENOV) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Enovis reported EPS of $0.78, above the $0.64 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +7.70%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.06
    Range$0.97 - $1.13
    15 analysts
    Revenue Consensus
    $618.46M
    Range$589.86M - $643.65M
    15 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.87
    Range$0.82 - $0.97
    7 analysts
    EPS Estimate DriftChange to current
    90d ago$1.00-12.8%
    60d ago$0.89-1.7%
    30d ago$0.89-2.4%
    7d ago$0.870.0%
    Current$0.87
    Revenue Consensus
    $612.92M
    Range$606.90M - $620.10M
    4 analysts

    Next Report

    ENOV has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 11.6% above the $0.95 reported for the quarter ended Dec 31, 2025.

    ENOV Earnings Call

    The latest ENOV earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ENOV beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $558.73M, up 1.8% from $548.91M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.78$0.64N/A+21.88%Beat+4.0%130 up, 2 downNov 5, 2026$558.73M
    Jun 30, 2026$0.76$0.79N/A-3.80%Miss-3.8%131 up, 8 downAug 6, 2026$582.78M
    Mar 31, 2026$0.89$0.81$0.74 - $0.86+9.88%Beat+9.9%112 up, 0 downMay 7, 2026$589.15M
    Dec 31, 2025$0.95$0.81$0.79 - $0.97+17.28%Beat-3.1%122 up, 1 downFeb 26, 2026$575.76M
    Sep 30, 2025$0.75$0.65$0.61 - $0.67+15.38%Beat+2.7%105 up, 4 downNov 6, 2025$548.91M
    Jun 30, 2025$0.79$0.74$0.62 - $0.78+6.76%Beat+27.4%115 up, 5 downAug 7, 2025$564.54M
    Mar 31, 2025$0.81$0.74$0.71 - $0.78+9.46%Beat+62.0%111 up, 0 downMay 8, 2025$558.83M
    Dec 31, 2024$0.98$0.92$0.90 - $0.95+7.02%Beat+24.1%110 up, 1 downFeb 26, 2025$560.98M
    Sep 30, 2024$0.73$0.61$0.58 - $0.68+19.67%Beat+30.4%110 up, 0 downNov 6, 2024$505.22M
    Jun 30, 2024$0.62$0.59$0.50 - $0.63+5.08%Beat+1.6%110 up, 1 downAug 7, 2024$525.16M
    Mar 31, 2024$0.50$0.48$0.38 - $0.54+4.17%Beat+13.6%100 up, 0 downMay 2, 2024$516.27M
    Dec 31, 2023$0.79$0.74$0.71 - $0.79+6.76%Beat+9.7%101 up, 0 downFeb 22, 2024$455.02M
    Sep 30, 2023$0.56$0.54$0.49 - $0.59+3.70%Beat-5.1%70 up, 0 downNov 7, 2023$417.52M
    Jun 30, 2023$0.61$0.52$0.50 - $0.56+17.31%Beat+3.4%70 up, 0 downAug 3, 2023$428.50M
    Mar 31, 2023$0.44$0.38$0.34 - $0.40+15.79%Beat+18.9%50 up, 0 downMay 4, 2023$406.15M
    Dec 31, 2022$0.72$0.66$0.52 - $0.69+9.09%Beat-59.3%70 up, 0 downFeb 23, 2023$408.71M
    Sep 30, 2022$0.59$0.48$0.44 - $0.50+22.92%Beat-63.6%80 up, 1 downNov 2, 2022$383.81M
    Jun 30, 2022$0.59$0.50$0.49 - $0.52+18.00%Beat-64.9%40 up, 0 downAug 4, 2022$395.12M
    Mar 31, 2022$0.37$0.35$0.34 - $0.36+5.71%Beat-72.0%20 up, 0 downMay 10, 2022$375.46M
    Dec 31, 2021$1.77$1.74N/A+1.72%Beat+15.7%N/AN/AFeb 22, 2022N/A
    Sep 30, 2021$1.62$1.61N/A+0.62%Beat+31.7%N/AN/ANov 4, 2021$359.92M
    Jun 30, 2021$1.68$1.61N/A+4.35%Beat+522.2%N/AN/AJul 28, 2021$356.12M
    Mar 31, 2021$1.32$1.19N/A+10.92%Beat+15.8%N/AN/AApr 29, 2021$879.21M
    Dec 31, 2020$1.53$1.49N/A+2.68%Beat-16.4%N/AN/AFeb 18, 2021N/A
    Sep 30, 2020$1.23$1.17N/A+5.13%Beat-18.0%N/AN/AOct 29, 2020$805.93M
    Jun 30, 2020$0.27$0.31N/A-12.85%Miss-83.3%N/AN/AAug 6, 2020$620.36M
    Mar 31, 2020$1.14$1.12N/A+1.79%Beat-28.3%N/AN/AMay 7, 2020$816.36M
    Dec 31, 2019$1.83$1.67N/A+9.58%Beat-11.6%N/AN/AFeb 21, 2020$888.37M
    Sep 30, 2019$1.50$1.42N/A+5.63%Beat-7.4%N/AN/AOct 31, 2019$846.52M
    Jun 30, 2019$1.62$1.84N/A-11.96%Miss-11.5%N/AN/AAug 6, 2019$908.65M
    Mar 31, 2019$1.59$1.48N/A+7.43%Beat+10.4%N/AN/AMay 8, 2019$683.92M
    Dec 31, 2018$2.07$1.90N/A+8.95%Beat+53.3%N/AN/AFeb 13, 2019$227.28M
    Sep 30, 2018$1.62$1.58N/A+2.53%Beat+28.6%N/AN/AOct 25, 2018$524.02M
    Jun 30, 2018$1.83$1.56N/A+17.31%Beat+41.9%N/AN/AAug 6, 2018$560.86M
    Mar 31, 2018$1.44$1.28N/A+12.50%Beat+37.1%N/AN/AMay 3, 2018$880.92M
    Dec 31, 2017$1.35$1.29N/A+4.65%Beat-2.2%N/AN/AFeb 6, 2018N/A
    Sep 30, 2017$1.26$1.23N/A+2.44%Beat+7.7%N/AN/ANov 6, 2017$844.51M
    Jun 30, 2017$1.29$1.29N/A0.00%In line+4.9%N/AN/AJul 28, 2017$847.96M
    Mar 31, 2017$1.05$0.89N/A+17.98%Beat+16.7%N/AN/AMay 5, 2017$733.63M
    Dec 31, 2016$1.38$1.32N/A+4.55%Beat-9.8%N/AN/AFeb 2, 2017$585.14M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.30, up 16.6% from the year before. It was $4.68 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.30+16.6%
    Dec 31, 2024$2.83+17.9%
    Dec 31, 2023$2.40+5.7%
    Dec 31, 2022$2.27-64.5%
    Dec 31, 2021$6.39+53.2%
    Dec 31, 2020$4.17-36.2%
    Dec 31, 2019$6.54-6.0%
    Dec 31, 2018$6.96+40.6%
    Dec 31, 2017$4.95+5.8%
    Dec 31, 2016$4.68N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,200 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,20715
    2026Q2Jun 30, 20267,02315
    2026Q1Mar 31, 20266,51314
    2025Q4Dec 31, 20256,32612
    2025Q3Sep 30, 20254,49712
    2025Q2Jun 30, 20256,63111
    2025Q1Mar 31, 20256,18812
    2024Q4Dec 31, 20246,77213

    2026Q3 Earnings Call

    Opening remarks

    Kyle William Rose Vice President of Investor Relations Good morning, everyone, and thank you for joining us today for our third quarter 2026 earnings conference call. I am Kyle William Rose, Vice President of Investor Relations. Joining me on the call this morning are Damien McDonald, Chief Executive Officer, and Ben Berry, our Chief Financial Officer. Our earnings release was issued earlier this morning and is available in the Investors section of our website, enovis.com. We also posted a slide presentation to accompany today's call on our website. Both the audio and the slide presentation of this call will be archived on our website later today. During this call, we will be making some forward-looking statements about our beliefs and estimates regarding future events and results, including statements related to our pending acquisition of Essential Robotics. These forward-looking statements are subject to risks and uncertainties, including those set forth in the Safe Harbor language in today's earnings release and in our filings with the SEC. Actual results might differ materially from any forward-looking statements that we make today. The forward-looking statements speak only as of today, and we do not assume any obligation to update them except as required by law. For further details regarding any non-GAAP financial measures referenced during this call, the accompanying reconciliation information can be found in our earnings press release and in the appendix of today's slide presentation. With that, let me turn the call over to Damien.

    Damien McDonald CEO Thanks, Kyle. Good morning, everyone, and thank you for joining us today. I will start with an overview of our third quarter results across Recon and P&R, and give a short update on Essential Robotics. Ben will then walk through the financials and our outlook for the fourth quarter and the full year before we open the call for questions. In the third quarter, we delivered organic growth of 5%, with 6% organic growth in Recon and 3% in P&R. In U.S. Recon, we grew 5% organically, with extremities up 5% and hips and knees up 3%. In extremities, we are now past the anniversary of the ARG launch, and ARG continues to be a strong growth opportunity for the future. As planned, ARVIS is expanding in shoulder, and we built upon the launch that began in Q2. Shoulder remains a healthy market, and it is where we have one of our leading share positions globally. In hips and knees, Nebula continues to drive growth, with over 80% of new instrumentation sets going to competitive users in the quarter. While we have now annualized the launch of Nebula in the U.S., we remain in the early stages of a multiyear product cycle.

    Frequently Asked Questions About ENOV

    When is Enovis's next earnings date?

    Enovis's next earnings report is expected for Feb 24, 2027.

    Did ENOV beat earnings estimates last quarter?

    Yes. Enovis reported EPS of $0.78 for the quarter ended Sep 30, 2026, above the $0.64 estimate, a 21.88% surprise.

    What EPS do analysts expect from ENOV next quarter?

    The consensus EPS estimate for Enovis for the quarter ending Dec 31, 2026 is $1.06 from 15 analysts, with estimates from $0.97 to $1.13.

    How often does ENOV beat earnings estimates?

    Enovis beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +10.48%.